DOCSLIB.ORG

Uclpartners Academic Health Science Partnership

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Uclpartners Academic Health Science Partnership UCLPartners academic health science partnership Professor the Lord Ajay Kakkar, Chair, UCLPartners Professor Sir David Fish, Managing Director, UCLPartners Dr Charlie Davie, Director of UCLPartners AHSN Clare Panniker, Chief Executive, Basildon and Thurrock University Hospitals NHS Foundation Trust What is UCLPartners? Six million population 23 healthcare organisations acute and 11 higher education institutes mental health trusts; community providers and research networks 20 Clinical Commissioning Groups (CCGs) Industry partnerships in research and 26 boroughs and local councils translation of innovation into health and wealth 2 Local Enterprise Partnership – key challenge • Working with the London Enterprise Panel, established by the Mayor of London • Professor Stephen Caddick, Vice Provost (Enterprise), UCL, is the only academic representative on the Panel • Key challenges of the panel: to compete with Boston and San Francisco; improve access to the NHS market to increase venture capital • How UCLPartners is contributing: working with industry to co-create technology and devices; creating long-term partnerships with industry and giving confidence to entrepreneurs, e.g. through new business models and procurement initiatives • Other areas of joint working: MedCity, Care City, London Health Commission, three London AHSNs and preparing to enable the success of the Francis Crick Institute 3 Defragmenting the pathway – an integrated journey to transform healthcare through innovation into practice Bringing together formal designations under one umbrella and working with partners to: Information • Discover new treatments and methods for Education improving health • Develop discoveries through clinical trials • Implement changes at scale and pace across the partnership Population • Evaluate how the system is working and what can be done next • Educate the workforce and develop capabilities • Use information to its best effect throughout the system 4 Example: Use of Natalizumab for multiple sclerosis DISCOVERY CLINICAL TRIALS IMPLEMENTATION EVALUATION CAPABILITY Surrogate “Real world” Treatment Educational markers and Phase 1-3 clinical evaluation received by publications and proof of concept trials clinical impact 112,000 patients clinical training studies and efficacy Relationships Patient pull Alignment Outcomes • Health improvement: 66% reduction in relapse, 50% reduction in relapse-related disability • Example of potential for economic gain: Natalizumab sales generated $1.6bn for Biogen in 2012 5 Business model Value add to population Value add to partner organisations UCLPartners turnover 6 Academic medical centre model for the AHSC INSTITUTE OF IMMUNITY & TRANSPLANTATION UCLH CANCER CENTRE BARTS UCL CANCER INSTITUTE CARDIOVASCULAR UCLPartners QUEEN SQUARE HOUSE MOORFIELDS / INSTITUTE OF OPHTHALMOLOGY CENTRE FOR CHILDREN’S RARE GOSHDISEASE & RESEARCHUCL Child Health 7 Population reach and impact through the AHSN AHSC PARTNERS nested in AHSN 8 Specialist cancer and cardiac services Benefits of improvements along whole pathway of care and to health economy: • 1,200 lives saved per year • Net present value gain of £94m • Globally competitive life sciences • International private practice Barts Heart Centre Cancer Centre at UCLH 9 Clinical trials Harmonisation North Thames Clinical Research Network Impact of harmonisation on approval times: ranks top nationally for recruitment median permission time (April to Aug 2014) 25,000 20,000 15,000 10,000 5,000 0 10 Quintiles Prime Site far exceeds the company recruitment target UCLPartners is the highest performer for Quintiles in Europe 11 Investing in genomics • UCLPartners, Cambridge and Newcastle Universities were the original partners in the Genomics England Rare Diseases Pilot • UCLPartners contributes 68% of the national sample DNA samples provided in Genomics Proposed governance structure of UCLPartners North England Rare Diseases Pilot (3 sites) West Genomic Medicine Centre 1400 NHS England / GEL 1200 1300 UCLPartners 1000 Executive Genomics Executive (Partnership Board) Board 800 then to UCLPartners Board 600 700 Genomics Operations Team 400 200 GOSH UCLH Moorfields NWLH RFH BH 0 Lead trust UCLPartners Cambridge and Newcastle Universities 12 Supporting people in London’s growth boroughs In Newham, UCLPartners is supporting: • Academic development of local people with £2m investment from Newham CCG and UCLPartners support to assist in the transformation of primary care • Establishment of an academic centre for health improvement science at the Sir Ludwig Guttmann Centre (the Olympic Medical Centre): potential scaling across London • Improvements in local health priorities through programmes on diabetes, cardiovascular disease, low birth weight babies and quality and capacity in primary care with a focus on health behaviours and inequalities • Children’s resilience through a mental health programme for young people, which has won £500k Big Lottery bid (with potential for £10m over five years) • University development in the Olympic park in potential collaboration with pharma 13 Supporting people in outer north east London • Supporting an innovative pilot primary care practice in Barking, Havering and Redbridge – delivering what matters most to 1,000 patients with most complex care needs • Care City – supporting local training and apprenticeships, informatics and industry • Life Study – largest ever cohort study of 80,000 children from birth to adulthood at Queen’s and King George hospitals, collaborating with CCG and other care providers 14 Mental health issues affect 1 in 4 people in England and have implications for employment Supporting workplace health and Improving wellbeing education & Getting employment people back outcomes in to work adolescents Better health and wealth Individual UK plc productivity Business productivity 15 New business model – shared risk, co-created, implemented Investment Value One-off seed funding of 25% for product maintenance UCLPartners £30,000 to and SME Concentra £10,000 profit 37.5% profit to UCLPartners (Concentra) Costs of 37.5% profit to Concentra £20,000 per More effective product and efficient care for patients £30,000 to £100,000 saving Recurring staff Client purchase (based on cost of cost savings of platform alternative platforms) £76k pa If this was rolled out across all local authorities total savings could be £15.2m plus recurrent annual savings of £11.5m 16 Innovation in informatics and data science Our approach to informatics • Connect the existing strengths the partnership has • Support partners to create a model of innovation that will save lives, transform services for patients and create value for organisations • Develop educational programmes for our clinical workforce • Expand industry partnerships Encouraging systemic innovation • UCLPartners is co-applicant and core partner of the only UK bid for the €600 million Knowledge Innovation Community in Healthy Living and Active Ageing – integrating Education, Research and Business • Aiming to create sustainable health systems across Europe, ready to tackle the challenges of our ageing population 17 Quality and safety • Value-based strategy based on Michael Porter’s work • Patient Safety Collaboratives • Sign up to Safety campaign • Partnership programmes are saving lives: • Collaboration across 15 trusts is reducing cardiac arrests in hospitals by up to 50% by identifying and responding to deteriorating patients 18 Atrial fibrillation – working together to save and improve lives Estimated Stage 2 bid for impact £500k to take UCLPartners to four more wide CCGs •>10% OACs •Clinical •Avoid 700 strokes pa Effectiveness •9% OACs •Avoid >50 strokes pa •Saves £8.4m pa NHS Group model •Saves >£600k pa NHS •Avoided 5 strokes pa costs = 10% OACs •Saves £60k pa NHS costs over 2 yrs. •Saves >£1m pa social •Saves £16m pa indirect costs social care costs Diffused to care costs Camden in 6 UCLPartners months diffuses across the partnership Atrial fibrillation community of interest Patient groups Local authority AHSNs CEG Providers SCNs Pharma Universities Med Tech NIC CCGs NICE 19 Stroke avoidance savings ref: Hunter et al 2013 Quality and value We must replace today’s fragmented system, in which every local provider offers a full range of services, with a system in which services for particular medical conditions are concentrated in health-delivery organizations and in the right locations to deliver high-value care. Prof Michael Porter, Harvard UCLPartners conference, City Hall, 2012 20.
Load more

Recommended publications
  • Biology Powerhouse Raises Railway Alarm
    NEWS IN FOCUS to enrol all participants by 2018. Certain factors make researchers optimis- tic that the British study will succeed where the US one failed. One is the National Health Service, which provides care for almost all pregnant women and their children in the United Kingdom, and so offers a centralized means of recruiting, tracing and collecting medical information on study participants. In the United States, by contrast, medical care is provided by a patchwork of differ- ent providers. “I think that most researchers in the US recognize that our way of doing population-based research here is simply different from the way things can be done in the UK and in Europe, and it will almost always be more expensive here,” says Mark Klebanoff, a paediatric epidemiologist at Nationwide Children’s Hospital in Colum- bus, Ohio, who was involved in early dis- cussions about the US study. The Francis Crick Institute sits at the nexus of three central London railway hubs. At one stage, US researchers had planned to knock on doors of random houses looking URBAN SCIENCE for women to enrol before they were even pregnant. “It became obvious that that wasn’t going to be a winning formula,” says Philip Pizzo, a paediatrician at Stanford University Biology powerhouse in Palo Alto, California, who co-chaired the working group that concluded that the National Children’s Study was not feasible. raises railway alarm “The very notion that someone was going to show up on your doorstep as a representa- tive from a govern­ment-funded study and Central London’s Francis Crick Institute fears that proposed say ‘Are you thinking of getting pregnant?’ train line will disrupt delicate science experiments.
    [Show full text]
  • Bloomsbury Scientists Ii Iii
    i Bloomsbury Scientists ii iii Bloomsbury Scientists Science and Art in the Wake of Darwin Michael Boulter iv First published in 2017 by UCL Press University College London Gower Street London WC1E 6BT Available to download free: www.ucl.ac.uk/ ucl- press Text © Michael Boulter, 2017 Images courtesy of Michael Boulter, 2017 A CIP catalogue record for this book is available from the British Library. This book is published under a Creative Commons Attribution Non-commercial Non-derivative 4.0 International license (CC BY-NC-ND 4.0). This license allows you to share, copy, distribute and transmit the work for personal and non-commercial use providing author and publisher attribution is clearly stated. Attribution should include the following information: Michael Boulter, Bloomsbury Scientists. London, UCL Press, 2017. https://doi.org/10.14324/111.9781787350045 Further details about Creative Commons licenses are available at http://creativecommons.org/licenses/ ISBN: 978- 1- 78735- 006- 9 (hbk) ISBN: 978- 1- 78735- 005- 2 (pbk) ISBN: 978- 1- 78735- 004- 5 (PDF) ISBN: 978- 1- 78735- 007- 6 (epub) ISBN: 978- 1- 78735- 008- 3 (mobi) ISBN: 978- 1- 78735- 009- 0 (html) DOI: https:// doi.org/ 10.14324/ 111.9781787350045 v In memory of W. G. Chaloner FRS, 1928– 2016, lecturer in palaeobotany at UCL, 1956– 72 vi vii Acknowledgements My old writing style was strongly controlled by the measured precision of my scientific discipline, evolutionary biology. It was a habit that I tried to break while working on this project, with its speculations and opinions, let alone dubious data. But my old practices of scientific rigour intentionally stopped personalities and feeling showing through.
    [Show full text]
  • Programme Final (1).Pages
    BSHS Postgraduate Conference 2015 Programme !1 The British Society for the History of Science is a company limited by guarantee: registration number 562208 and charity number 258854. BSHS Executive Secretary PO Box 3401, Norwich NR7 7JF (+44) 01603516236 Email: offi[email protected] Webpage: www.bshs.org.uk © 2014, British Society for the History of Science !2 BSHS POSTGRADUATE CONFERENCE UCL Department of Science and Technology Studies 7 – 8 – 9 JANUARY 2015 The Department of Science and Technology Studies at University College London welcomes you to the BSHS Postgraduate Conference 2015! This event is an annual conference for postgraduate scholars in the history, philosophy and sociology of science, technology and medicine interested in meeting and sharing research with other postgraduate scholars. This is a great opportunity to build professional and social networks within a supportive and constructive environment. We had an outstanding response for paper submissions and postgraduate attendance, and we are looking forward to an extraordinary conference this year. Thank you for your contribution! Sincerely, BSHS Postgraduate Conference 2015 Committee Elizabeth Jones Raquel Velho Erman Sozudogru !3 " !4 Blue: Grey: Yellow: Grant Museum of Zoology UCL Roberts Building Holiday Inn Bloomsbury 21 University Street Torrington Place Coram Street London WC1E 6DE London WC1E 7JE London WC1N 1HT CONFERENCE INFORMATION Webpage: http://www.bshs.org.uk/conferences/postgraduate-conference/2015- postgraduate-conference-ucl Facebook: https://www.facebook.com/BSHS.PG.15
    [Show full text]
  • 2021 Phd Projects and Supervisory Teams Doctoral Fellowships for Clinicians
    2021 PhD projects and supervisory teams Doctoral Fellowships for Clinicians The role of “persistent PAMPs” in the cytokine storm and ARDS during severe COVID-19 and highly pathogenic influenza infection. Supervisory team: David Bauer (primary supervisor, Crick) and Mahdad Noursadeghi (UCL). Inflammation associated with SARS-CoV-2 infection. Supervisory team: Rupert Beale (primary supervisor, Crick) and Wendy Barclay (Imperial College London) Effect of acute myeloid leukaemia on normal haematopoiesis. Supervisory team: Dominique Bonnet (primary supervisor, Crick) and David Taussig (The Institute of Cancer Research, Royal Marsden) Investigation and modelling of multiple myeloma pathogenetic evolution. Supervisory team: Dinis Calado (primary supervisor, Crick), Richard Houlston (The Institute of Cancer Research) and Martin Kaiser (The Institute of Cancer Research, Royal Marsden) TGF-b family ligands as potential therapeutic targets in pancreatic cancer. Supervisory team: Caroline Hill (primary supervisor, Crick) and Debashis Sarker (King’s College London) Development of multisynaptic tracing technologies to target and manipulate disease- relevant neural circuits. Supervisory team: Johannes Kohl (primary supervisor, Crick), Andrew Murray (UCL) and Rickie Patani (Crick/UCL) Human Cell Atlas: single-cell transcriptomics of vitiligo. Supervisory team: Nicholas Luscombe (primary supervisor, Crick), Magnus Lynch (King’s College London) and John Ferguson (King’s College London) Structural and biochemical analysis of Salmonella effector functions and their interaction with host proteins. Supervisory team: Katrin Rittinger (primary supervisor, Crick), Teresa Thurston (Imperial College London) and Rupert Beale (Crick) Developing new viral vectors for in vivo gene therapy. Supervisory team: Sam Rodriques (primary supervisor, Crick), Matthew Walker (UCL) and Rob Brownstone (UCL) Identifying and functionally characterising non-coding drivers of renal cancer evolution.
    [Show full text]
  • Applying Polygenic Risk Scoring for Psychiatric Disorders to a Large
    http://www.diva-portal.org This is the published version of a paper published in . Citation for the original published paper (version of record): de Jong, S., Abdalla Diniz, M J., Saloma, A., Gadelha, A., Santoro, M L. et al. (2018) Applying polygenic risk scoring for psychiatric disorders to a large family with bipolar disorder and major depressive disorder Communications Biology, 1: 163 https://doi.org/10.1038/s42003-018-0155-y Access to the published version may require subscription. N.B. When citing this work, cite the original published paper. Permanent link to this version: http://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-157800 ARTICLE DOI: 10.1038/s42003-018-0155-y OPEN Applying polygenic risk scoring for psychiatric disorders to a large family with bipolar disorder and major depressive disorder Simone de Jong1,2, Mateus Jose Abdalla Diniz3,4, Andiara Saloma3,4, Ary Gadelha3, Marcos L. Santoro5, 1234567890():,; Vanessa K. Ota3,5, Cristiano Noto3, Major Depressive Disorder and Bipolar Disorder Working Groups of the Psychiatric Genomics Consortium#, Charles Curtis1,2, Stephen J. Newhouse2,6,7, Hamel Patel2,6, Lynsey S. Hall8, Paul F. O`Reilly1, Sintia I. Belangero3,5, Rodrigo A. Bressan3 & Gerome Breen 1,2 Psychiatric disorders are thought to have a complex genetic pathology consisting of interplay of common and rare variation. Traditionally, pedigrees are used to shed light on the latter only, while here we discuss the application of polygenic risk scores to also highlight patterns of common genetic risk. We analyze polygenic risk scores for psychiatric disorders in a large pedigree (n ~ 260) in which 30% of family members suffer from major depressive disorder or bipolar disorder.
    [Show full text]
  • Clinical Academic Leadership in COVID-19: a Rapid Leader: First Published As 10.1136/Leader-2020-000292 on 1 July 2020
    Brief report Clinical academic leadership in COVID-19: a rapid leader: first published as 10.1136/leader-2020-000292 on 1 July 2020. Downloaded from response to sharing emerging insights in intensive care Nirandeep Rehill,1,2 Amanda Begley,1 Katie Mantell,1 C Michael Roberts1 1UCL Partners, London, UK ABSTRACT assume that role. UCLPartners is a partnership of 2 NIHR Applied Health Research Background The COVID-19 pandemic has raised a 23 National Health Service (NHS) trusts and 9 North Thames, London, UK wide range of challenges for health systems around the higher education institutions covering north central world and the National Health Service in England has and east London and parts of Essex, Hertfordshire Correspondence to Dr Amanda Begley, UCL been no exception. A significant proportion of infected and Bedfordshire. Governed by a partnership board Partners, London W1T 7HA, UK; cases require intensive care unit support and have a high and led by clinical academics supported by a corpo- amanda. begley@ uclpartners. mortality rate. In the early stages of the pandemic, there rate senior team, its purpose is to bring together com was neither an evidence base nor a clinical consensus on organisations to work collaboratively for the health and care of the population served. Received 18 May 2020 the optimal management of patients in this setting. Revised 9 June 2020 Interventions Responding to requests for assistance Accepted 11 June 2020 to address this evidence gap, UCLPartners, an Academic SHARING EMERGING INSIGHTS Health Science Partnership, working in collaboration with Through our partnership, we received intelligence other organisations including National Institute of Health that clinicians were concerned that the traditional Research Applied Research Collaboration North Thames, management of ARDS and other complications was developed a clinical academic team to synthesise clinical not having expected outcomes against this novel learning in real time.
    [Show full text]
  • Dr Charlie Davie, Managing Director, Uclpartners
    Collaborating with industry and researchers to deliver improved healthcare Dr Charlie Davie, Managing Director, UCLPartners UCLPartners – a partnership organisation Parts of London, Bedfordshire, Hertfordshire and Essex 6 million 46 11 population Healthcare Higher education organisations and partners clinical commissioners 844 100s 6 primary care practices industry partnerships Sustainability and Transformation Partnerships A unique business model UCLPartners aligns the following functions in one partnership: • Academic Health Science Centre (AHSC) • Academic Health Science Network (AHSN) • NIHR Collaboration for Applied Health Research and Care (CLAHRC/ARC) • Commercial Trials Prime Site • NIHR Clinical Research Network (CRN) • Genomic Medicine Centre 5 Life Sciences Industrial Strategy • Science: Continued support for the science base, maintaining strength and international competitiveness. • Growth: An environment that encourages companies to start and grow, building on strengths across the UK, including expansion of manufacturing in the sector. • NHS: NHS and industry collaboration, facilitating better care for patients through better adoption of innovative treatments and technologies. • Data: Making the best use of data and digital tools to support research and better patient care. • Skills: Ensuring that the sector has access to a pool of talented people to support its aims through a strong skills strategy. 6 7 The Accelerated Access Review Aim: To speed up access to innovation and grow the UK life sciences industry Recommendations in five key areas: 1. Patients, clinicians and charities to be the key drivers in innovation 2. A new accelerated access pathway will prioritise innovations 3. Open and transparent pathways to bring forward medtech, digital and diagnostics 4. Driving innovation through NHS planning, increasing capacity, clinical leadership and incentives 5.
    [Show full text]
  • Theme 1: Development of the Cambridge Biomedical Campus (CBC)
    ACADEMIC HEALTH SCIENCE CENTRES SPECIFIC THEME / WORK PROGRAMME 1. DETAILS OF THE PROPOSED ACADEMIC HEALTH SCIENCE CENTRE (AHSC) Name of the English NHS Provider/University Partnership: Cambridge University Health Partners 2. THEME / WORK PROGRAMME 2.1 Name of the theme/work programme. Theme 1: Development of the Cambridge Biomedical Campus (CBC) 2.2 Aims and objective of the theme/work programme. Since 1999 CUHFT, UoC and the MRC have been jointly committed to a strategy of expansion and development of their shared site as the CBC. The campus has doubled in size from 70 acres in 2006 to 140 acres today, with options to extend by a further 17 acres by 2040. The existing site provides a remarkable environment, largely because of the wide range of occupants spanning service, education, research and innovation interests. These include: (1) NHS : CUHFT (Addenbrooke’s and the Rosie Maternity Hospital), selected services of CPFT, NHS Blood and Transplant, and a base for the East Anglian Ambulance Services Trust; (2) University of Cambridge: School of Clinical Medicine with its 12 departments and the Cancer Research UK Cambridge Institute, the Wellcome Trust-MRC Institute of Metabolic Science, the Institute for Public Health and the Wellcome Trust Cambridge Institute for Medical Research (3) Medical Research Council: the Laboratory of Molecular Biology, the Mitochondrial Biology Unit and the Biostatistics Unit (4) Pharmaceutical companies: GlaxoSmithKline Clinical Research Unit Cambridge, AstraZeneca (from 2016) (5) Multiprofessional Education; the Deakin Centre, providing a range of high quality community services combined with excellent education and training provision; (6) within a five minute walk is the Strangeways Research Laboratory, home to the University’s Centre for Genetic Epidemiology and the Public Health Genomics Foundation.
    [Show full text]
  • Health Tech Innovator Drdoctor Gains Three New NHS Contracts
    Press release Health tech innovator DrDoctor gains three new NHS contracts Patient appointment innovator DrDoctor is working with three new major NHS Trusts: • A major children’s hospital, where the system is being configured in record time and will manage the Trust’s 150000 specialist outpatient appointments • Whittington Health NHS Trust, covering all appointments across the Trust • University Hospital Southampton NHS Foundation Trust, DrDoctor is piloting in Paediatrics to demonstrate an estimated 30% DNA rate reduction DrDoctor supports hospitals with digital transformation. Its system allows patients to view, change and schedule outpatient appointments themselves, online, on smartphone or by conversational SMS. DrDoctor chief executive Tom Whicher said: “We are thrilled to support three more forward thinking Trusts in their journey to provide effective, digital first, patient centric services. All three implementations will deliver, in year cash savings, increase patient satisfaction and form a strong foundation for future digital transformation.” DrDoctor reduces the number of missed and unscheduled appointments and allows patients to opt in to receiving paperless communications, releasing print and postage savings to Trusts. New analysis at Guy’s and St Thomas’ NHS Foundation Trust has revealed that in one year the Trust has saved £2.2m, and patient satisfaction is 96 percent. DrDoctor is supporting a major London children’s hospital’s strategic plan to become the leading paediatric centre in the world. DrDoctor was engaged in January 2017 to deploy its Appointment Management Platform. DrDoctor’s platform is a fundamental shift away from an inconsistent approach to appointment management. The platform will go-live in the summer of 2017.
    [Show full text]
  • The Francis Crick Institute
    Clinical Medicine 2017 Vol 17, No 2: 105–7 PROFESSIONAL ISSUES T h e F r a n c i s C r i c k I n s t i t u t e A u t h o r s : K e i t h P e t e r s A a n d J i m S m i t h B The Francis Crick Institute Laboratory, opened in 2016, is sup- is within easy reach of GlaxoSmithKine (GSK) and Astra ported by the Medical Research Council, Cancer Research UK, Zeneca’s principal research laboratories in Stevenage and the Wellcome Trust, and University College London, King’s Col- Cambridge, respectively. lege London and Imperial College London. The emphasis on But in order to justify investment on the scale required, the research training and early independence of gifted scientists new institute needed to be more than a simple translocation to ABSTRACT in a multidisciplinary environment provides unique opportuni- a new site. ties for UK medical science, including clinical and translational After discussion and negotiation, the MRC, Cancer Research research. UK (CRUK), the Wellcome Trust and University College London (UCL) created a partnership: CRUK’s London Research K E Y W O R D S : MRC , CRUK , Wellcome , Crick , UCL , King’s , Imperial Institute (LRI) would join the NIMR, with researchers from UCL contributing expertise in the physical and clinical sciences. Importantly, the Crick was not simply to be a merger The Francis Crick Institute has been referred to as the most of LRI and NIMR but a new entity with a different ethos – a significant development in UK biomedical science for a multidisciplinary institute with a substantial new investment in generation.
    [Show full text]
  • Trustees' Annual Report and Financial Statements 31 March 2016
    THE FRANCIS CRICK INSTITUTE LIMITED A COMPANY LIMITED BY SHARES TRUSTEES’ ANNUAL REPORT AND FINANCIAL STATEMENTS 31 MARCH 2016 Charity registration number: 1140062 Company registration number: 6885462 The Francis Crick Institute Accounts 2016 CONTENTS INSIDE THIS REPORT Trustees’ report (incorporating the Strategic report and Directors’ report) 1 Independent auditor’s report 12 Consolidated statement of financial activities 13 Balance sheets 14 Cash flow statements 15 Notes to the financial statements 16 1 TRUSTEES’ REPORT (INCORPORATING THE STRATEGIC REPORT AND DIRECTORS’ REPORT) The trustees present their annual directors’ report together with the consolidated financial statements for the charity and its subsidiary (together, ‘the Group’) for the year ended 31 March 2016, which are prepared to meet the requirements for a directors’ report and financial statements for Companies Act purposes. The financial statements comply with the Charities Act 2011, the Companies Act 2006, and the Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK (FRS102) effective 1 January 2015 (Charity SORP). The trustees’ report includes the additional content required of larger charities. REFERENCE AND ADMINISTRATIVE DETAILS The Francis Crick Institute Limited (‘the charity’, ‘the Institute’ or ‘the Crick) is registered with the Charity Commission, charity number 1140062. The charity has operated and continues to operate under the name of the Francis Crick
    [Show full text]
  • Developing the Evidence Base for London's Local Industrial Strategy
    Developing the evidence base for London’s Local Industrial Strategy - Interim report August 2019 Developing the evidence base for London’s Local Industrial Strategy - Interim report copyright Greater London Authority August 2019 Published by Greater London Authority City Hall The Queens Walk London SE1 2AA www.london.gov.uk Tel 020 7983 4000 Minicom 020 7983 4000 ISBN 978-1-84781-719-8 Cover photograph © Shutterstock For more information about this publication, please contact: GLA Economics Tel 020 7983 4000 Email [email protected] GLA Economics provides expert advice and analysis on London’s economy and the economic issues facing the capital. Data and analysis from GLA Economics form a basis for the policy and investment decisions facing the Mayor of London and the GLA group. GLA Economics uses a wide range of information and data sourced from third party suppliers within its analysis and reports. GLA Economics cannot be held responsible for the accuracy or timeliness of this information and data. The GLA will not be liable for any losses suffered or liabilities incurred by a party as a result of that party relying in any way on the information contained in this report. Acknowledgements GLA Economics would like to thank all colleagues at the GLA and in other organisations who contributed to this report, including: • Members of the Analytical Working Group, especially the ONS regional statisticians (Sukriti Verma and Tom Liu) for all their work on developing London-relevant statistics; • Gerard Burgess and Jorn Peters in the GLA Planning Directorate for their very valuable comments and contributions to Chapters 7 and 8; • Professor Stephen Roper at the Enterprise Research Centre (Warwick Business School) for his valuable advice on Chapter 6; • The LIS Evidence Base Independent Expert Panel – Professor Riccardo Crescenzi, Dr.
    [Show full text]